HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Progabid
Gabren · Gabrene · SL-76．002 · progabide · Halogabide · C-abren(e) · Progabide USP/EP/BP · Progabide, 10 mM in DMSO
Identifikatoren & physikalische Daten
| CAS No. | 104880-78-6 |
|---|---|
| Summenformel | C17H16ClFN2O2 |
| Durchschnittliche Molmasse | 334,8 g/mol |
| SMILES | NC(=O)CCCN=C(c1ccc(Cl)cc1)c1cc(F)ccc1O |
| InChIKey | IBALRBWGSVJPAP-UHFFFAOYSA-N |
| PubChem CID | 44115 |
| ChEMBL | CHEMBL287631 |
| ChEBI | CHEBI:135422 |
| EC No. | 263-679-4 |
| DTXSID | DTXSID00878140 |
| Lokaler Name | Progabid |
Chemische & physikalische Eigenschaften
| XLogP | 3 |
|---|---|
| Polarare Oberfläche (TPSA) | 75,7 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 6 |
| Schwere Atome | 23 |
| Formalladung | 0 |
| Komplexität | 425 |
| Arzneimittel | Pharmaceuticals -> Nervous system -> AntiepilepticsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 2.97 |
| Schmelzpunkt | 133-135 °C133-135°mp 142.5° (Kaplan, J. Med. Chem.) |
| Siedepunkt | 525.4±50.0 °C(Predicted) |
| Dichte | 1.2822 (estimate) |
| Lagerbedingungen | 2-8°C |
| Löslichkeit | Chloroform (Slightly, Sonicated), DMSO, Methanol (Slightly, Sonicated)37.16mg/L(37 ºC) |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | pKa 3.41 ± 0.04(0.4% MeOH,t=37,Iundefined)(Approximate) |
| Farbe | Light Yellow to Yellow |
| CAS Datenbank | 62666-20-0 |
Sicherheit & Vorschriften
| Gesundheitliche Auswirkungen | May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease. |
|---|---|
| Expositionspfade | Well absorbed with a bioavailability of 60% |
| Toxizitätsübersicht | Progabide binds to both GABA<sub>A</sub> and GABA<sub>B</sub> receptors located on the terminals of primary afferent fibers. Binding to GABA<sub>A</sub> results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABA<sub>B</sub> receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Toxizität | LD50 i.p. in mice: 900 mg/kg (Kaplan) |
Anwendungen & Verwendung
Beschreibung
Progabide is a broad-spectrum anticonvulsant agent indicated for the treatment of a wide variety of seizure disorders. Synthesized as a GABA-prodrug, anticonvulsant activity appears due to the parent drug and its acid metabolite, as well as to GABAmide and GABA liberated therefrom.
Verwenden
Progabide is a gamma-aminobutyric acid (GABA) antagonist with antiepileptic activity.